GC
TOVX icon

Guggenheim Capital’s Theriva Biologics TOVX Stock Holding History

Guggenheim Capital’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed -$5K – 2591
2018
Q1 		$5K Hold
2
– – ﹤0.01% 2777
2017
Q4 		$7K Hold
2
– – ﹤0.01% 2695
2017
Q3 		$13K Hold
2
– – ﹤0.01% 2772
2017
Q2 		$8K Hold
2
– – ﹤0.01% 2814
2017
Q1 		$10K Hold
2
– – ﹤0.01% 2817
2016
Q4 		$13K Hold
2
– – ﹤0.01% 2872
2016
Q3 		$28K Hold
2
– – ﹤0.01% 2795
2016
Q2 		$30K Hold
2
– – ﹤0.01% 2790
2016
Q1 		$34K Buy
2
+1
+100% +$15K ﹤0.01% 2805
2015
Q4 		$29K Hold
1
– – ﹤0.01% 2904
2015
Q3 		$29K Buy
+1
New +$24.6K ﹤0.01% 2877
2014
Q3 		– Sell
-2
Closed -$25K – 3110
2014
Q2 		$25K Hold
2
– – ﹤0.01% 3148
2014
Q1 		$42K Buy
2
+1
+100% +$20.7K ﹤0.01% 3156
2013
Q4 		$16K Buy
+1
New +$12.6K ﹤0.01% 3148

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Guggenheim Capital's TOVX Position: Q2 2018 in Review

Guggenheim Capital sold out of Theriva Biologics (TOVX) in Q2 2018, closing a stake of 2 shares — an estimated $5K sold.

Guggenheim Capital first reported a position in TOVX in Q4 2013 and held it in 14 quarters. The position peaked at $42K in Q1 2014. 46 funds tracked by Wall St. Rank hold TOVX as of Q2 2018.

  • Guggenheim Capital reported no remaining Theriva Biologics position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 2 Theriva Biologics shares in Q2 2018, an estimated $5K.
  • Guggenheim Capital first reported a position in Theriva Biologics in Q4 2013 and held it in 14 quarters.
  • Guggenheim Capital's Theriva Biologics position peaked at $42K in Q1 2014.
  • 46 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.